Concise review: Parthenote stem cells for regenerative medicine: Genetic, epigenetic, and developmental features

Brittany Daughtry, Shoukhrat Mitalipov

    Research output: Contribution to journalArticle

    27 Citations (Scopus)

    Abstract

    Embryonic stem cells (ESCs) have the potential to provide unlimited cells and tissues for regenerative medicine. ESCs derived from fertilized embryos, however, will most likely be rejected by a patient's immune system unless appropriately immunomatched. Pluripotent stem cells (PSCs) genetically identical to a patient can now be established by reprogramming of somatic cells. However, practical applications of PSCs for personalized therapies are projected to be unfeasible because of the enormous cost and time required to produce clinical-grade cells for each patient. ESCs derived from parthenogenetic embryos (pESCs) that are homozygous for human leukocyte antigens may serve as an attractive alternative for immunomatched therapies for a large population of patients. In this study, we describe the biology and genetic nature of mammalian parthenogenesis and review potential advantages and limitations of pESCs for cell-based therapies.

    Original languageEnglish (US)
    Pages (from-to)290-298
    Number of pages9
    JournalStem cells translational medicine
    Volume3
    Issue number3
    DOIs
    StatePublished - 2014

    Fingerprint

    Regenerative Medicine
    Epigenomics
    Stem Cells
    Embryonic Stem Cells
    Pluripotent Stem Cells
    Cell- and Tissue-Based Therapy
    Embryonic Structures
    Parthenogenesis
    Complementary Therapies
    HLA Antigens
    Immune System
    Costs and Cost Analysis
    Population

    Keywords

    • Histocompatibility
    • Imprinting
    • Parthenogenesis
    • Pluripotent stem cells

    ASJC Scopus subject areas

    • Cell Biology
    • Developmental Biology

    Cite this

    Concise review : Parthenote stem cells for regenerative medicine: Genetic, epigenetic, and developmental features. / Daughtry, Brittany; Mitalipov, Shoukhrat.

    In: Stem cells translational medicine, Vol. 3, No. 3, 2014, p. 290-298.

    Research output: Contribution to journalArticle

    @article{df0ffbf9a785417ab1c9642990ce67b4,
    title = "Concise review: Parthenote stem cells for regenerative medicine: Genetic, epigenetic, and developmental features",
    abstract = "Embryonic stem cells (ESCs) have the potential to provide unlimited cells and tissues for regenerative medicine. ESCs derived from fertilized embryos, however, will most likely be rejected by a patient's immune system unless appropriately immunomatched. Pluripotent stem cells (PSCs) genetically identical to a patient can now be established by reprogramming of somatic cells. However, practical applications of PSCs for personalized therapies are projected to be unfeasible because of the enormous cost and time required to produce clinical-grade cells for each patient. ESCs derived from parthenogenetic embryos (pESCs) that are homozygous for human leukocyte antigens may serve as an attractive alternative for immunomatched therapies for a large population of patients. In this study, we describe the biology and genetic nature of mammalian parthenogenesis and review potential advantages and limitations of pESCs for cell-based therapies.",
    keywords = "Histocompatibility, Imprinting, Parthenogenesis, Pluripotent stem cells",
    author = "Brittany Daughtry and Shoukhrat Mitalipov",
    year = "2014",
    doi = "10.5966/sctm.2013-0127",
    language = "English (US)",
    volume = "3",
    pages = "290--298",
    journal = "Stem cells translational medicine",
    issn = "2157-6564",
    publisher = "AlphaMed Press",
    number = "3",

    }

    TY - JOUR

    T1 - Concise review

    T2 - Parthenote stem cells for regenerative medicine: Genetic, epigenetic, and developmental features

    AU - Daughtry, Brittany

    AU - Mitalipov, Shoukhrat

    PY - 2014

    Y1 - 2014

    N2 - Embryonic stem cells (ESCs) have the potential to provide unlimited cells and tissues for regenerative medicine. ESCs derived from fertilized embryos, however, will most likely be rejected by a patient's immune system unless appropriately immunomatched. Pluripotent stem cells (PSCs) genetically identical to a patient can now be established by reprogramming of somatic cells. However, practical applications of PSCs for personalized therapies are projected to be unfeasible because of the enormous cost and time required to produce clinical-grade cells for each patient. ESCs derived from parthenogenetic embryos (pESCs) that are homozygous for human leukocyte antigens may serve as an attractive alternative for immunomatched therapies for a large population of patients. In this study, we describe the biology and genetic nature of mammalian parthenogenesis and review potential advantages and limitations of pESCs for cell-based therapies.

    AB - Embryonic stem cells (ESCs) have the potential to provide unlimited cells and tissues for regenerative medicine. ESCs derived from fertilized embryos, however, will most likely be rejected by a patient's immune system unless appropriately immunomatched. Pluripotent stem cells (PSCs) genetically identical to a patient can now be established by reprogramming of somatic cells. However, practical applications of PSCs for personalized therapies are projected to be unfeasible because of the enormous cost and time required to produce clinical-grade cells for each patient. ESCs derived from parthenogenetic embryos (pESCs) that are homozygous for human leukocyte antigens may serve as an attractive alternative for immunomatched therapies for a large population of patients. In this study, we describe the biology and genetic nature of mammalian parthenogenesis and review potential advantages and limitations of pESCs for cell-based therapies.

    KW - Histocompatibility

    KW - Imprinting

    KW - Parthenogenesis

    KW - Pluripotent stem cells

    UR - http://www.scopus.com/inward/record.url?scp=84896279403&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84896279403&partnerID=8YFLogxK

    U2 - 10.5966/sctm.2013-0127

    DO - 10.5966/sctm.2013-0127

    M3 - Article

    C2 - 24443005

    AN - SCOPUS:84896279403

    VL - 3

    SP - 290

    EP - 298

    JO - Stem cells translational medicine

    JF - Stem cells translational medicine

    SN - 2157-6564

    IS - 3

    ER -